Cel­lec­tis signs $760M mile­stone deal with NK up­start; Im­muno­core brings on As­traZeneca vet to shep­herd bis­pe­cif­ic launch plans

Af­ter near­ly two decades as of­ten one of the on­ly com­pa­nies de­vel­op­ing off-the-shelf CAR-Ts, Cel­lec­tis has in re­cent years racked up big-name part­ner­ships, in­clud­ing with Arie Bellde­grun’s Al­lo­gene and French gi­ant Servi­er.

Now they’ve teamed with a lit­tle known start­up that has yet to an­nounce a Se­ries A: New York-based Cy­tovia Ther­a­peu­tics. The two com­pa­nies an­nounced on Tues­day a deal to de­vel­op uni­ver­sal gene-edit­ed nat­ur­al killer cells and CAR-NK cells for sol­id tu­mors and oth­er can­cers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.